Report

reporttype2Version of Safety Report ID2receivedateformat102transmissiondateformat102fulfillexpeditecriteria1Safety Report ID10033970serious1Date Last Updated25/03/2014receiptdateformat102companynumbUS-ROCHE-1321752occurcountryUSseriousnessother1duplicate1Date Received25/03/2014transmissiondate02/10/2014primarysourcecountryUS

Primary Source

reportercountryUSqualification1

Patient

Weight194SexFemale

Contents

Reaction
- 1)
- 2)
- 3)
- 4)
- 5)
Drug

Reaction

1)

reactionmeddraversionpt17.0ReactionPlatelet count decreasedOutcomeUnknown

2)

reactionmeddraversionpt17.0ReactionWhite blood cell count decreasedOutcomeUnknown

3)

reactionmeddraversionpt17.0ReactionBlood count abnormalOutcomeUnknown

4)

reactionmeddraversionpt17.0ReactionPancytopeniaOutcomeUnknown

5)

reactionmeddraversionpt17.0ReactionAnaemiaOutcomeUnknown

Drug

1)

drugcharacterization1medicinalproductPEGASYSdrugbatchnumbUNKNOWNdrugauthorizationnumb103964drugstructuredosagenumb180drugstructuredosageunit004drugseparatedosagenumb1drugintervaldosageunitnumb1drugintervaldosagedefinition803drugdosagetextROTATING SITES (THIGH OR ABDOMEN),drugdosageformSOLUTION FOR INJECTIONdrugadministrationroute030drugindicationHEPATITIS Cdrugstartdateformat102drugstartdate28/10/2013actiondrug5

openFDA Info on Medication

Application NumberBLA103964Brand NamePEGASYSGeneric NamePEGINTERFERON ALFA-2AManufacturersGenentech, Inc.product_ndc0004-0350, 0004-0357Product TypeHUMAN PRESCRIPTION DRUGRouteSUBCUTANEOUSActive IngredientsPEGINTERFERON ALFA-2ARXCUI351270, 352297, 731326, 731328spl_id5e9bb3e4-48f9-4b34-9c4f-7a6f27ffd98cspl_set_idde61685e-2b8c-4e22-84bb-869e13600440Package NDC0004-0350-09, 0004-0357-30NUIN0000175521, M0025711Established Pharmacologic ClassInterferon alpha [EPC]Chemical StructureInterferon-alpha [CS]UNIIQ46947FE7K

2)

drugcharacterization1medicinalproductPEGASYSdrugbatchnumbUNKNOWNdrugauthorizationnumb103964drugstructuredosagenumb180drugstructuredosageunit004drugadministrationroute058drugstartdateformat102drugstartdate25/02/2014actiondrug5

openFDA Info on Medication

3)

drugcharacterization1medicinalproductCOPEGUSdrugauthorizationnumb021511drugstructuredosagenumb600drugstructuredosageunit003drugseparatedosagenumb1drugintervaldosageunitnumb12drugintervaldosagedefinition805drugdosagetext600MG IN THE MORNING, 600MG AT NIGHTdrugadministrationroute048drugindicationHEPATITIS Cdrugstartdateformat102drugstartdate28/10/2013actiondrug5

4)

drugcharacterization1medicinalproductCOPEGUSdrugauthorizationnumb021511drugseparatedosagenumb1drugintervaldosageunitnumb1drugintervaldosagedefinition804drugdosagetextDOSE REDUCEDdrugadministrationroute048drugstartdateformat102drugstartdate25/02/2014actiondrug5

5)

drugcharacterization1medicinalproductINCIVEKdrugstructuredosagenumb750drugstructuredosageunit003drugseparatedosagenumb3drugintervaldosageunitnumb1drugintervaldosagedefinition804drugdosagetext3X A DAYdrugadministrationroute065drugindicationPRODUCT USED FOR UNKNOWN INDICATIONactiondrug5

6)

drugcharacterization2medicinalproductVITAMIN D3drugstructuredosagenumb2000drugstructuredosageunit025drugseparatedosagenumb1drugintervaldosageunitnumb1drugintervaldosagedefinition804drugdosagetext2000 UNITS DAILYdrugadministrationroute065

openFDA Info on Medication

Application NumberANDA090455Brand NameVITAMIN DGeneric NameERGOCALCIFEROLManufacturersStrides Pharma Science Limitedproduct_ndc64380-737Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsERGOCALCIFEROLRXCUI1367410spl_id08a99dff-5765-49b0-b289-4e854d3c6725spl_set_id2c4c0a36-12cf-444d-9d57-de983eef4d36Package NDC64380-737-06, 64380-737-25NUIM0007651, N0000175909Chemical StructureErgocalciferols [CS]Established Pharmacologic ClassProvitamin D2 Compound [EPC]UNIIVS041H42XC

7)

drugcharacterization2medicinalproductSERTRALINEdrugstructuredosagenumb50drugstructuredosageunit003drugseparatedosagenumb1drugintervaldosageunitnumb1drugintervaldosagedefinition804drugadministrationroute065

openFDA Info on Medication

Application NumberANDA077670, ANDA077864, ANDA077397Brand NameSERTRALINEGeneric NameSERTRALINE, SERTRALINE HYDROCHLORIDEManufacturers Lupin Pharmaceuticals, Inc., Hikma Pharmaceuticals USA Inc., Exelan Pharmaceutic ... product_ndc 68180-351, 68180-352, 68180-353, 0143-9655, 0143-9656, 0143-9654, 76282-212, 762 ... Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsSERTRALINE HYDROCHLORIDERXCUI312938, 312940, 312941spl_id 78d3579a-260f-4bb2-95f2-8ee8a60fae18, f35de481-61af-428e-abb4-a267238b3959, 5c8d ... spl_set_id 42120ff8-b353-4632-9ea9-54de9a698724, f9641190-9151-4f7e-89ff-1e7a818c30ee, 2dac ... Package NDC 68180-351-06, 68180-351-08, 68180-351-09, 68180-351-01, 68180-351-03, 68180-352- ... UNIIUTI8907Y6X

8)

drugcharacterization2medicinalproductTRAMADOLdrugstructuredosagenumb50drugstructuredosageunit003drugseparatedosagenumb1drugintervaldosageunitnumb6drugintervaldosagedefinition805drugdosagetext1 EVERY 6 HOURS IF NEEDEDdrugadministrationroute065

9)

drugcharacterization2medicinalproductSOVALDI

openFDA Info on Medication

Application NumberNDA204671, NDA212480Brand NameSOVALDIGeneric NameSOFOSBUVIRManufacturersGilead Sciences, Inc.product_ndc61958-1501, 61958-1503, 61958-1504, 61958-1505Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsSOFOSBUVIRRXCUI1484916, 1484922, 2203891, 2203893, 2203993, 2203999, 2204090, 2204092spl_idb6ff385d-224a-0bad-e053-2995a90adcd4spl_set_id80beab2c-396e-4a37-a4dc-40fdb62859cfPackage NDC61958-1501-1, 61958-1503-1, 61958-1504-1, 61958-1505-1NUIN0000191493, N0000191258, N0000175459Established Pharmacologic ClassHepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC]Mechanism of ActionRNA Replicase Inhibitors [MoA]UNIIWJ6CA3ZU8B

Report Duplicate

duplicatesourceROCHEduplicatenumbUS-ROCHE-1321752

Receiver

receivertype6receiverorganizationFDA

Sender

sendertype2senderorganizationFDA-Public Use

Adverse Event Report

Report

Primary Source

Patient

Reaction

1)

2)

3)

4)

5)

Drug

1)

openFDA Info on Medication

2)

openFDA Info on Medication

3)

4)

5)

6)

openFDA Info on Medication

7)

openFDA Info on Medication

8)

9)

openFDA Info on Medication

Report Duplicate

Receiver

Sender

Media

Newsletter

Follow us

Connect with us